Cancer Management and Research (Sep 2024)
Impact of Chemotherapy on Circulating Lymphocyte Subsets in Lung Cancer Patients
Abstract
Wei Hong,1 Lei Zhang,1 Youkun Qi,2 Yanjun Wang,1 Wentao Wang3 1Oncology, The Second People’s Hospital of Liaocheng, Liaocheng, Shandong, People’s Republic of China; 2Pharmacy, The Second People’s Hospital of Liaocheng, Liaocheng, Shandong, People’s Republic of China; 3Critical Care Medicine, The Second People’s Hospital of Liaocheng, Liaocheng, Shandong, People’s Republic of ChinaCorrespondence: Wentao Wang, Critical Care Medicine, The Second People’s Hospital of Liaocheng, Liaocheng, Shandong, People’s Republic of China, Email [email protected]: Lung cancer remains a leading cause of cancer-related death and chemotherapy stands as a fundamental component in therapy. Chemotherapy-induced myelosuppression encompasses a spectrum of hematological declines, including not only neutrophils but also lymphocytes, hemoglobin levels and platelets. This retrospective cohort study investigates alterations in peripheral blood lymphocyte subsets. By uncovering these changes, our goal is to refine patient management strategies, ensuring that the benefits of chemotherapy are maximized while minimizing its detrimental effects.Patients and Methods: We retrospectively analyzed 159 lung cancer patients. Patients were categorized as “NT” (n=108, no previous anti-tumor therapy), and “PT” (n=51, prior therapy followed by at least a two-month treatment-free interval). Post-chemotherapy, patients were reassessed and grouped into “EarlyCycle” for those who underwent four or fewer cycles, and “LateCycle” for those who underwent more than four cycles.Results: The study focused on analyzing the percentages of lymphocyte subsets, including T cells (CD4+, CD8+), B cells, and natural killer (NK) cells, across these groups. For T cells, the EarlyCycle group exhibited a significant increase compared to NT (0.7783 vs 0.7271; p=0.0017) and PT (0.7783 vs 0.6804; p=1.6e-05). B cells showed a significant decrease from NT to LateCycle (0.1014 vs 0.0817; p=2.2e-05) and from PT to LateCycle (0.1317 vs 0.0817; p=6.2e-10). NK cells significantly decreased in the EarlyCycle group compared to NT (0.1109 vs 0.1462; p=0.00816) and PT (0.1109 vs 0.1513; p=0.00992), with no significant change in the LateCycle group compared to either NT or PT (p> 0.05).Conclusion: Chemotherapy significantly affects lymphocyte subsets in a treatment-specific manner. The EarlyCycle group experienced a reduction in NK cell and an increase in T cell, suggesting a damage of innate immunity and an early shift towards adaptive immunity. The LateCycle group showed a substantial decrease in B cell, indicating a delayed effect on humoral immunity components.Keywords: chemotherapy, lung cancer, myelosuppression, peripheral blood, lymphocyte subsets
